April 20th, 2015
Selections from Richard Lehman’s Literature Review: April 20th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include the efficacy and safety of both alirocumab and evolocumab in reducing lipids and CV events, survival and outcomes following bioprosthetic vs. mechanical mitral valve replacement, and more.
March 15th, 2015
More Information Emerges About the PCSK9 Inhibitors
Larry Husten, PHD
New information emerged today about two new cholesterol-lowering drugs that have been attracting a lot of attention. Data about the PCSK9 inhibitors — evolocumab, under development by Amgen, and alirocumab, under development by Sanofi and Regeneron — were presented at the American College of Cardiology meeting in San Diego and published simultaneously in the New England Journal of Medicine. […]
October 6th, 2014
Selections from Richard Lehman’s Literature Review: October 6th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include medical device safety and effectiveness, familial hypercholesterolemia, and more.
May 27th, 2014
Selections from Richard Lehman’s Literature Review: May 27th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include mortality trends in patients with diabetes, cardiovascular remodeling in CAD and HF, and more.
NEJM Journal Watch — Recent Cardiology Articles- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?
- Can Genetic and Social Risk Scores Improve Cardiac Risk Prediction?
- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?
- Are Angiographically-Derived Coronary Physiology Measurements Ready for Use in the Cath Lab?